Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,017.70 -7.58 (-0.74%)
Streaming Delayed Price Updated: 10:43 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
News headline image
Members of Congress Are Pouring Millions Into These 7 Surprising Stocks ↗
Via The Motley Fool
News headline image
Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’ ↗
Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share,... 
Via Stocktwits
News headline image
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
News headline image
Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition ↗
Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions. 
Via Benzinga
News headline image
Is the Market Bullish or Bearish on Eli Lilly? ↗
 
Via Benzinga
News headline image
May 2025 Industrial Manufacturing Near March 2025 Levels with 146 New Planned Capital Projects Heading into Summer
JACKSONVILLE, Fla., June 17, 2025 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads announced today the May 2025 results for its new planned capital project spending report for the Industrial... 
Via Send2Press
News headline image
Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks ↗
The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies. 
Via Stocktwits
News headline image
Why Novo Nordisk Stock Sank by Nearly 4% Today ↗
Via The Motley Fool
News headline image
These 2 Growth Stocks Are No-Brainer Buys Right Now ↗
Via The Motley Fool
News headline image
Could Meta and Eli Lilly Trigger the Next Stock Split Boom?
Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices. 
Via MarketBeat
News headline image
Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499 ↗
Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access without insurance barriers. 
Via Benzinga
News headline image
Eli Lilly To Offer Highest Doses Of Weight-Loss Medicine On Its Digital Health Platform, But Retail Wants More Good News ↗
Healthcare providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will start in early August. 
Via Stocktwits
Topics Stocks
News headline image
Bila Solar’s Indiana Factory Commences Production of Domestic Solar Panels, Strengthening U.S. Clean Energy Manufacturing at Key Policy Moment
Behind-the-scenes video captures this milestone for American solar — creating local jobs and reinforcing why federal support for clean energy matters 
Via News Direct
Topics Economy
News headline image
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks? ↗
Via The Motley Fool
Topics Government
News headline image
3 Growth Stocks You Can Buy Right Now Without Any Hesitation ↗
Via The Motley Fool
News headline image
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock? ↗
Via The Motley Fool
News headline image
Benzinga Bulls And Bears: Eli Lilly, Okto, McDonalds — And Israel-Iran Conflict Sparks Oil Surge ↗
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
News headline image
1 Growth Stock Down 9% to Buy Right Now ↗
Via The Motley Fool
News headline image
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased ↗
Jefferies thinks big pharma companies are "still on the hunt" for deals. 
Via Stocktwits
News headline image
$1000 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock ↗
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential. 
Via Benzinga
News headline image
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company ↗
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions. 
Via Benzinga
News headline image
Down 12%, Should You Buy the Dip on Eli Lilly? ↗
Via The Motley Fool
News headline image
3 Healthcare Stocks with Questionable Fundamentals
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
News headline image
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor? ↗
Via The Motley Fool
News headline image
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility ↗
Via The Motley Fool
Topics Artificial Intelligence Government
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 to Avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice ↗
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned. 
Via Benzinga
News headline image
Eli Lilly Inks Pact With Juvena Therapeutics To Develop Muscle-Boosting Drugs ↗
Eli Lilly signed a licensing deal with Juvena for muscle health using its AI-enabled stem-cell protein screening platform. 
Via Benzinga
News headline image
Hims & Hers Stock Falls After Eli Lilly Rules Out Telehealth Tie-Up: Citi Calls It Aggressive Stance, Retail Turns Bearish ↗
If Hims were to align with Lilly, Citi warned, it would signal the company has "thrown in the towel" on compounded medications. 
Via Stocktwits
Topics Regulatory Compliance
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.